Compounding pharmacies operated in a regulatory gray zone, using AOD-9604 as a bulk drug substance before FDA formally restricted it
In contrast, parenteral administration, which includes intravenous, intramuscular, and subcutaneous injections, stands out because it bypasses first-pass hepatic metabolism, providing nearly complete bioavailability of the active substance
The pattern mirrors other side effects: worst during the first week at a new dose, gradual improvement over weeks 2 and 3, often resolution or significant improvement by week 4 at the same dose
mTORC1 is a major regulatory node in the FGF21 signaling network in adipocytes
Safe dosages are: Children: 65 mg/kg/day for six months Teenagers: 20 and 40 milligrams per kilogram of body weight for 3 to 6 months